CDXS vs. IPSC, OGI, XFOR, DSGN, RIGL, PSTX, ZVRA, CMPX, GALT, and ELEV
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Century Therapeutics (IPSC), Organigram (OGI), X4 Pharmaceuticals (XFOR), Design Therapeutics (DSGN), Rigel Pharmaceuticals (RIGL), Poseida Therapeutics (PSTX), Zevra Therapeutics (ZVRA), Compass Therapeutics (CMPX), Galectin Therapeutics (GALT), and Elevation Oncology (ELEV). These companies are all part of the "medical" sector.
Century Therapeutics (NASDAQ:IPSC) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
In the previous week, Century Therapeutics had 5 more articles in the media than Codexis. MarketBeat recorded 7 mentions for Century Therapeutics and 2 mentions for Codexis. Codexis' average media sentiment score of 0.65 beat Century Therapeutics' score of 0.45 indicating that Century Therapeutics is being referred to more favorably in the media.
Codexis has a net margin of -108.69% compared to Codexis' net margin of -6,115.12%. Century Therapeutics' return on equity of -47.58% beat Codexis' return on equity.
Codexis received 316 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 61.14% of users gave Codexis an outperform vote while only 60.00% of users gave Century Therapeutics an outperform vote.
Century Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 7.6% of Century Therapeutics shares are held by insiders. Comparatively, 6.3% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Codexis has higher revenue and earnings than Century Therapeutics. Codexis is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics presently has a consensus target price of $13.60, suggesting a potential upside of 329.02%. Codexis has a consensus target price of $6.80, suggesting a potential upside of 120.06%. Given Codexis' stronger consensus rating and higher possible upside, research analysts plainly believe Century Therapeutics is more favorable than Codexis.
Summary
Codexis beats Century Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
